Top Stories
Roche launches new Elevidys Phase 3 trial targeting European approval after prior regulatory shortfalls in Duchenne gene therapy
Roche is initiating a new Phase 3 trial for Elevidys, the micro-dystrophin gene therapy it commercializes in partnership with Sarepta Therapeutics, in an effort to secure approval in Europe and other markets where the therapy has not yet been authorized, according to STAT News. The decision reflects the European Medicines Agency's historical demand for functional outcome data beyond the surrogate biomarker endpoints that supported the US accelerated approval pathway. As Endpoints News reported, prior regulatory discussions in Europe were complicated by trial design debates and the contested nature of micro-dystrophin expression as a surrogate endpoint for clinical benefit. Elevidys carries a US list price of approximately $3.2 million per dose and is approved in the US for ambulatory patients aged 4 and older with a confirmed mutation in the DMD gene. The Duchenne population in Europe represents a meaningful incremental opportunity, with an estimated 15,000 to 20,000 patients across the EU. Key open questions include trial endpoint selection, patient stratification by age and ambulation status, and whether functional data from the ongoing ENVISION trial will be incorporated into the European dossier.
Johnson & Johnson exits MeiraGTx eye disease gene therapy after Phase 3 failure, returning bota-vec for $25 million buyback
Johnson & Johnson is returning botaretigene sparoparvovec, known as bota-vec, to MeiraGTx following a Phase 3 trial failure in a rare retinal disease indication, with MeiraGTx paying $25 million upfront to reacquire full rights, as Fierce Biotech reported. The transaction structure is notable: rather than Johnson & Johnson simply terminating the collaboration, MeiraGTx is paying to recover the asset, suggesting residual internal conviction around the program despite the clinical setback. Bota-vec targets CNGB3-associated achromatopsia, a rare inherited retinal condition affecting cone photoreceptor function, with a US patient population estimated in the low thousands. The Phase 3 failure raises questions about trial design, patient selection, and the challenge of demonstrating functional visual improvement in achromatopsia trials, where endpoint sensitivity has historically been debated. For MeiraGTx, reclaiming the asset preserves optionality to redesign the program, pursue alternative regulatory pathways, or seek a new partner at a later stage. The deal also reflects a broader pattern of large pharma reassessing their gene therapy collaboration portfolios as clinical-stage programs encounter late-stage attrition.
Elevidys European strategy and MeiraGTx bota-vec reversal illustrate divergent gene therapy regulatory and commercial trajectories
The near-simultaneous announcements from Roche on Elevidys and Johnson & Johnson on bota-vec frame a useful contrast in gene therapy program management. Roche is investing further capital in a new confirmatory trial to meet EMA evidentiary standards for a therapy already generating US revenue, accepting the cost and timeline of additional clinical work rather than forgoing the European market. MeiraGTx, by contrast, is reclaiming a Phase 3 failure for $25 million, preserving the option to reposition or redesign without a large partner's strategic constraints. According to Endpoints News, Elevidys has faced sustained scrutiny over whether micro-dystrophin expression translates to meaningful functional outcomes, a debate that directly shaped the EMA's posture. The bota-vec situation, as Fierce Biotech noted, adds to a series of ocular gene therapy late-stage disappointments that have tempered investor expectations in the retinal space. Together, these developments raise questions about how sponsors calibrate investment in additional trials against commercial returns in geographies with high evidentiary bars, particularly for one-time therapies priced above $3 million.
Pipeline Watch
Roche's new Phase 3 trial for Elevidys will need to address the EMA's resistance to micro-dystrophin as a standalone surrogate endpoint, according to STAT News. The trial's choice of primary endpoint, whether the North Star Ambulatory Assessment or a timed function measure, will carry implications for how other DMD gene therapy developers structure their own European regulatory dossiers.
MeiraGTx has paid $25 million to recover full rights to bota-vec following the Phase 3 failure, as Fierce Biotech reported. The company retains the manufacturing infrastructure and clinical data package from the prior trial, which could support a redesigned study with revised endpoints or a refined patient selection strategy targeting younger patients with greater photoreceptor preservation.
Terremoto Biosciences has closed a $108 million Series C financing round to advance its selective AKT1 inhibitor pipeline across oncology and the rare vascular disorder hereditary hemorrhagic telangiectasia (HHT), as Pharmaceutical Technology reported. The round was led by new investors including RA Capital Management and Deep Track Capital, with participation from existing backers OrbiMed, Third Rock Ventures, and Novo Holdings. Terremoto is advancing two clinical-stage programs: TER-2013 in oncology indications and TER-1754 targeting HHT, a rare inherited condition affecting blood vessel formation with limited approved treatment options. The financing follows a $175 million Series B in 2023 and brings total funding to over $350 million. The HHT program represents a notable rare disease application of covalent AKT1 inhibition, a mechanism more commonly pursued in oncology settings.
Competitive Landscape
The bota-vec Phase 3 failure adds to a pattern of late-stage disappointments in inherited retinal disease gene therapy. Programs targeting achromatopsia, choroideremia, and other rare retinal conditions have encountered endpoint sensitivity challenges, raising questions about whether current functional vision measures adequately capture treatment benefit in slowly progressing conditions.
| Program | Company | Indication | Stage |
|---|---|---|---|
| Bota-vec | MeiraGTx (post-buyback) | CNGB3 Achromatopsia | Phase 3 Failed / Reassessing |
| Luxturna (voretigene) | Spark / Roche | RPE65 LCA | Approved (US/EU) |
| CPCB-RPE1 | jCyte | Retinitis Pigmentosa | Phase 2b |
| AAV-RPGR | MeiraGTx | RPGR-RP | Phase 2/3 |
With Elevidys approved in the US but absent from Europe, Roche faces a bifurcated market position for a therapy priced at $3.2 million. The new Phase 3 trial is unlikely to yield results before 2029 at the earliest, creating a window in which European DMD patients continue on exon-skipping antisense or standard of care while the gene therapy market matures in the US.
Johnson & Johnson's return of bota-vec reflects a recalibration of how large pharma manages gene therapy portfolio risk after Phase 3 failure. The $25 million buyback, rather than a simple termination, suggests negotiated terms that preserved MeiraGTx optionality while allowing Johnson & Johnson to recover some invested capital and exit the program cleanly.
Forward Looking
- Roche Elevidys Phase 3 trial design details, including primary endpoint selection and patient stratification criteria, will be the critical near-term disclosure to track for EMA approval prospects.
- MeiraGTx next strategic move on bota-vec, whether a redesigned trial, new partner search, or pivot to earlier-line achromatopsia patients, represents an open question with licensing implications for the ocular gene therapy space.
- European payer and HTA readiness for a $3.2 million Duchenne gene therapy will remain a parallel track question even if Roche achieves EMA approval, given NICE and G-BA cost-effectiveness hurdle rates.
- Whether other large pharma partners holding rare disease gene therapy collaborations conduct similar portfolio reviews following the Johnson & Johnson bota-vec exit is worth monitoring across the next two quarters.